|
|
|
09111
|
|
|
P.I.:
|
Przemyslaw Twardowski, MD
|
|
|
Title:
|
AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy
|
| | |
|
|
08025
|
|
|
P.I.:
|
Przemyslaw Twardowski, MD
|
|
|
Title:
|
Phase II Randomized Trial of Gemcitabine and Cisplatin with or without Cetuximab in Patients with Urothelial Carcinoma
|
| | |
|
|
08024
|
|
|
P.I.:
|
Przemyslaw Twardowski, MD
|
|
|
Title:
|
PHII-84, NCI#7659; A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage DO Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy
|
| | |
|
|
08012
|
|
|
|
07013
|
|
|
P.I.:
|
Przemyslaw Twardowski, MD
|
|
|
Title:
|
A Phase II Trial of Dasatinib (Sprycel) in Subjects with Hormone-Refractory Prostate Cancer, Previously Treated with Chemotherapy
|
| | |
|